Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT A DICHMANN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1245232578
CMS profile
328270
Location
SANTA MARIA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$26.48

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $26.48 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Astellas Pharma US Inc $26.48 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT A DICHMANN

NPI 1245232578 · CMS profile ID 328270

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SANTA MARIA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1245232578?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT A DICHMANN, NPI 1245232578, CMS profile ID 328270. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245232578?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ROBERT A DICHMANN, NPI 1245232578, CMS profile ID 328270. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245232578?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ROBERT A DICHMANN, NPI 1245232578, CMS profile ID 328270, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1245232578?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $26.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $26.4806/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034160385 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $328.73 22
PY2020 $104.19 8
PY2021 $18.12 2
PY2022 $14.08 1
PY2023 $26.48 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,981.45 2
PY2024 Principal investigator $7,185.45 2
PY2023 Principal investigator $33,549.76 11
PY2022 Principal investigator $162,021.03 21
PY2021 Principal investigator $97,528.06 21
PY2020 Principal investigator $227,117.30 35
PY2019 Principal investigator $393,411.87 53

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $2,779.87 12/31/2021 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY CORPORATION
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy No dispute reported 06/30/2026 848744873
Principal investigator 1 Seagen Inc. $200.00 10/18/2021 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 792662079
Principal investigator 1 Seagen Inc. $200.00 10/18/2021 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 792662085
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,000.00 08/10/2021 Non-covered Recipient Entity
Translational Oncology Research International
A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks. No dispute reported 06/30/2026 819902851
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,714.00 08/04/2021 Non-covered Recipient Entity
Translational Oncology Research International
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices No dispute reported 06/30/2026 819902705
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,301.00 07/27/2021 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY INC
MONALEESA 3 A RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED STUDY OF RIBOCICLIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHO HAVE RECEIVED NO OR ONLY ONE LINE OF PRIOR ENDOCRINE TREATMENT No dispute reported 06/30/2026 800646793
Principal investigator 1 Merck Sharp & Dohme Corporation $250.00 07/26/2021 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY CORPORATION
A Randomized open-Label Phase III Trial of Pembrolizumab versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 848742943
Principal investigator 1 Seagen Inc. $2,000.00 07/26/2021 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 792662063
Principal investigator 1 MorphoSys AG $25,474.00 06/24/2021 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - L-MIND No dispute reported 06/30/2026 854739665
Principal investigator 1 EMD Serono, Inc. $500.00 06/15/2021 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY-US INC
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842924249
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,420.00 06/11/2021 Non-covered Recipient Entity
Translational Oncology Research International
Phase IIB 1L NSCLC Flat Dose Nivo Combo Schedule Safety No dispute reported 06/30/2026 819902953
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,801.00 06/11/2021 Non-covered Recipient Entity
Translational Oncology Research International
Phase III Multiple Myeloma 3L Combo nivo - elo No dispute reported 06/30/2026 819903041
Principal investigator 1 Seagen Inc. $200.00 04/27/2021 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 792662057
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $680.00 03/23/2021 Non-covered Recipient Entity
Translational Oncology Research International
Phase IIIB/IV Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previous Untreated, Advanced or Metastatic RCC No dispute reported 06/30/2026 819902749
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $12,549.00 03/17/2021 Non-covered Recipient Entity
Translational Oncology Research International
Phase III 1L Metastatic RCC Nivo Ipi Cabo No dispute reported 06/30/2026 819902985
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $21,029.00 02/11/2021 Non-covered Recipient Entity
Translational Oncology Research International
An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CheckMate 627) No dispute reported 06/30/2026 819902731
Principal investigator 1 MorphoSys AG $500.00 02/11/2021 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - L-MIND No dispute reported 06/30/2026 854739687
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,091.67 01/28/2021 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
RIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE No dispute reported 06/30/2026 800626211
Principal investigator 1 Incyte Corporation $1,097.00 01/20/2021 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES No dispute reported 06/30/2026 831078207
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,670.00 01/19/2021 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
RIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE No dispute reported 06/30/2026 800626203
Principal investigator 1 Novartis Pharmaceuticals Corporation $71.52 01/15/2021 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
TWO ARM RANDOMIZED PHASE 3 STUDY IN HIGH RISK NSCLC COMPARING CANAKINUMAB VS PLACEBO IN ADJUVANT SETTING No dispute reported 06/30/2026 800625583